Addressing the psychiatric and cognitive symptoms of Huntington's Disease through targeted, non-invasive brain stimulation to improve quality of life.
Huntington's Disease progressively damages the basal ganglia and cortex. TMS targets the surviving neural circuits to optimize their function, slow symptom progression, and improve daily life.
A hereditary neurodegenerative disorder that progressively destroys neurons in the basal ganglia and cerebral cortex.
Huntington's Disease (HD) is caused by an expansion of the CAG trinucleotide repeat in the HTT gene, leading to progressive degeneration of the striatum (caudate nucleus and putamen) and later the cerebral cortex. This neuronal loss produces the classic triad of motor, cognitive, and psychiatric symptoms.
While HD is a genetic condition with no current cure, the psychiatric and cognitive symptoms—which often emerge years before motor symptoms—are among the most distressing for patients and families. Depression affects up to 40% of HD patients, and irritability, apathy, and executive dysfunction severely impair daily functioning and independence.
Emerging research suggests that TMS may have neuroprotective properties, potentially promoting brain-derived neurotrophic factor (BDNF) release—a protein critical for neuronal survival that is depleted in HD.
Modulating cortical circuits that compensate for basal ganglia dysfunction to improve mood, cognition, and motor control.
In Huntington's Disease, the cortex attempts to compensate for the failing basal ganglia by reorganizing its own circuits. TMS can support this compensatory process by strengthening cortical activity in regions that are still functional, particularly the dorsolateral prefrontal cortex (DLPFC) for depression and executive function, and the supplementary motor area (SMA) for motor control.
High-frequency rTMS to the DLPFC has shown promise in alleviating the severe depression and apathy that accompanies HD. Additionally, protocols targeting motor areas can help modulate the cortical hyperexcitability that contributes to chorea (involuntary movements), offering a non-pharmacological alternative to drugs like tetrabenazine that often worsen depression.
Assessment of motor, cognitive, and psychiatric symptoms to identify priority brain targets and develop a personalized protocol.
Precise magnetic pulses to the DLPFC for mood and cognition, and SMA for motor symptoms, adapted to the patient's disease stage.
Regular reassessment and protocol adjustment as HD progresses, ensuring TMS continues to target the most impactful symptoms.
Targeting both the psychiatric burden and the motor dysfunction of Huntington's Disease.
Activating the underactive prefrontal cortex to lift the pervasive depression and motivational deficit seen in HD.
Modulating cortical excitability to help reduce the involuntary, dance-like movements characteristic of HD.
Supporting executive function, attention, and processing speed by stimulating the prefrontal cortex networks.
Restoring prefrontal inhibitory control over emotional responses to reduce outbursts and improve social functioning.
Regulating circadian rhythm disruptions common in HD through modulation of cortical arousal networks.
Modulating the cortico-striatal circuits involved in the obsessive and anxious features frequently seen in HD.
| Feature | Standard HD Medications | TMS Therapy |
|---|---|---|
| Depression Treatment | SSRIs—may worsen motor symptoms in some patients. | Directly activates prefrontal mood circuits without systemic effects. |
| Chorea Management | Tetrabenazine—effective but commonly worsens depression. | Modulates cortical excitability without depleting dopamine. |
| Cognitive Support | No approved pharmacological options available. | Enhances prefrontal cortex function and BDNF release. |
| Side Effects | Sedation, weight gain, worsened mood, parkinsonism. | Zero systemic side effects. Well-tolerated. |
Addressing the full triad of HD symptoms—motor, cognitive, and psychiatric—through targeted neuromodulation.
TMS protocols are adjusted based on the patient's current HD stage—from pre-manifest gene carriers experiencing only psychiatric symptoms to those with advanced motor involvement.
Research indicates TMS promotes BDNF release—a key neurotrophic factor depleted in HD. This may support neuronal survival and slow the trajectory of cognitive decline.
TMS works alongside existing HD medications, potentially allowing dose reductions of drugs like tetrabenazine that carry significant psychiatric side effects.
Dr. Amin recognizes the unique challenge Huntington's Disease presents—a condition where standard psychiatric medications can worsen motor symptoms, and motor medications can worsen mood. TMS offers a way to treat the psychiatric and cognitive dimensions of HD without these pharmacological trade-offs, giving patients and families meaningful improvements in quality of life.
Read Full BiographyHear from patients whose lives were transformed through Dr. Amin's care.
If medications aren't adequately managing the psychiatric or cognitive symptoms of HD, explore how targeted TMS can help.
Non-invasive. Non-pharmacological. Discover how TMS can address the psychiatric and cognitive burden of Huntington's Disease.
Book Your Consultation Today